Persistent Systems Ltd. share price target

We expect Persistent Systems to report a strong Q1FY27 with USD revenue of USD 449.6 Mn (+3.1% QoQ, +15.4% YoY), reflecting continued execution on large deal ramp ups and strength across BFSI and Healthcare verticals.

Currently, the company is trading at 27x/23x P/E multiples of FY27E/FY28E. We value the company at 34x FY28E EPS and maintain our BUY rating on the stock with an unchanged TP of Rs 6,270/share, implying an upside of 46% from the CMP.

On 27 June 2026, PSYS announced a very large acquisition (Nagarro - 75% of current revenue) and a large net new deal

Transaction Overview: Persistent (via German subsidiary Galaxy Germany Holding SE / BidCo) announced voluntary public takeover offer for all shares of Nagarro SE (Frankfurt-listed) at EUR 81/share in cash (~140% premium to its undisturbed closing price on June 25, 2026, & ~94% premium to 3M VWAP). It has already secured binding 21% stake from Nagarro's largest shareholder Lantano Beteiligungen GmbH (Carl-Georg Drschmidt) while Nagarro's management has expressed intent to tender its shares (~13-14%), taking effective committed stake to ~3540%. The minimum acceptance threshold is...

Acquisition to be funded by bridge loan facility of EUR 1.4 bn The investments (USD 1.6bn) in Nagarro is largely complementing and scaling the core business dynamics of PSYS, in terms of expanding new verticals and geographies, where PSYS has marginal presence. More importantly, the target entity shares a similar culture and service lines to PSYS' core business, which is a positive in our view. However, we believe there is a slight business risk which comes along with the vertical presence, barring 2-3 verticals, the near-term growth within other business units remains a challenge (mid-single-digit). PSYS is largely pivoted on the build side...

Persistent Systems announced two strategic developments: the acquisition of Nagarro for an enterprise value of €1.27b, and a new USD650m+ services contract over 6.5 years with an existing US-based technology customer.

We expect BFSI to be the strongest vertical and could lead growth in FY27E, followed by healthcare and hitech, although SaaS remains relatively softer, AI and license revenue, coupled with Sasva and iAura, continue to provide PSYS with a competitive edge over the market for now.

FY27 revenue run-rate target of $2 Billion. Al adoption expected to accelerate across clients. EBIT margin aspiration of 16-17%. Continued growth across BFSI, Healthcare & Technology.

AI-led strategy driving differentiation and deal momentum: The company's AI-first approach, built on engineering hyper productivity, business process optimization and enterprise data readiness, is gaining strong traction across clients. Persistent has built a differentiated ecosystem with 500+ AI agents and partnerships across hyperscalers, strengthening its positioning in next-gen deals. Strong ACV growth of 27.1% YoY and continued large deal wins reflect increasing relevance in AI-led transformation programs. Management's continued investments in AI capabilities and platforms are expected to drive...

Persistent Systems’ outlook is defined by its seamless transition into a premier, AI-led digital engineering powerhouse.

We maintain our BUY rating on the stock.

Persistent posted robust results for another quarter with 3.4% q/q cc revenue growth to $436mn aided by a healthy order book (LTM TCV up 14.4% y/y) along with continued large-account mining and resilient growth across major client buckets, with all customer buckets growing at roughly 19% to 21% y/y in FY26.

Persistent’s top line came in a tad short of consensus expectations; yet, its Q4 growth outpaced peers. Despite high exposure to product engineering—a segment vulnerable to AI disruption—the company is successfully pivoting to capture AI-led revenue.

4QFY26 tad weaker than estimate on both revenue and margins. US$2bn revenue run rate is likely in 4QFY27. Still be a growth leader

Steady Growth, Slight Miss on Estimates in Q4 Deal wins impacted by seasonality in Q4 The revenue performance (+3.4% QoQ CC) was below our estimates (+4.3% QoQ CC), attributed to passing productivity benefits to its marquee accounts. Barring this impact, the execution remained strong in terms of winning new business ACV, grew 37.7% YoY in Q4 and 22.7% YoY in FY26. Despite the escalating geo-political tension, management expects growth momentum to continue within all three verticals. The deployment of products and solutions benefits in terms of optimizing resources and...

Persistent Systems (PSYS) reported 4QFY26 revenue of USD436m (vs. est. USD438m), up 3.2% QoQ in USD terms and 3.4% in CC (est. +3.5%). Adj. EBIT margin stood at 16.3% (est. 16.6%).

Persistent sustained its ‘consistent compounding’ narrative for another quarter with 4.1% q/q and 17.3% y/y CC revenue growth to $423mn aided by a healthy order book along with (LTM TCV up 14.2% y/y) continued deepening of its large-client relationships.

Persistent Systems’ (PSYS) strong revenue growth of 4.1% QoQ CC in a furlough quarter (Q3FY26) was aided by an increase in software license sales (up 44% QoQ USD) and healthy growth in services business (+2.6% QoQ USD).

Inline revenue. Margin surprise on sale of AI Software licenses. The US$2bn FY27 goal may require an acquisition

Consistent growth engine with strong deal visibility: Persistent continues to demonstrate a structurally strong growth profile (+4.1% QoQ CC) and robust booking momentum. Rising TCV (US$674.5 mn - up 11% QoQ/13.5% YoY) and ACV (US$501.9 mn - up 12% QoQ/17% YoY) reflects improving revenue visibility, driven by deeper participation in large, strategic client programs. Demand remains healthy across verticals, supported by application and data modernization themes in BFSI and healthcare. The management noted that it remains firmly on track toward its US$2 bn revenue aspiration by FY27,...